Use of parasitic biological agents for prevention and control of autoimmune diseases
CA 2315790 C · Owner: University Of Iowa Research Foundation · Inventors: Weinstock, Joel V.; Elliott, David E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis both known as IBD. While , the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally rheumatoid arthritis, type 1 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 11, 1998 and granted October 6, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 11, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 11, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.